Frey NA, Peng S, Cheng K, et al. Magnetic nanoparticles: synthesis, functionalization, and applications in bioimaging and magnetic energy storage. Chem Soc Rev. 2009;38:2532–2542
Jun Y, Choi J, Cheon J., Heterostructured magnetic nanoparticles: their versatility and high performance capabilities. Chem Comm. 2007;1203–1214
Ambashta RD, Sillanpää M., Water purification using magnetic assistance: a review. J Hazard Mater. 2010;180:38–49
Cheng Z, Tan ALK, Tao Y, et al. Synthesis and characterization of iron oxide nanoparticles and applications in the removal of heavy metals from industrial wastewater. Int J Photoenergy. 2012;2012:1–5
Wu W, Wu Z, Yu T, et al. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater. 2015;16:1–43
Reimer P, Schuierer G, Balzer T, et al. Application of a superparamagnetic iron oxide (Resovist®) for MR imaging of human cerebral blood volume. Magn Reson Med. 1995;34:694–697
Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003;13:1266–1276
Taboada E, Rodríguez E, Roig A, et al. Relaxometric and magnetic characterization of ultrasmall iron oxide nanoparticles with high magnetization. Evaluation as potential T1 magnetic resonance imaging contrast agents for molecular imaging. Langmuir. 2007;23:4583–4588
Kim BH, Lee N, Kim H, et al. Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents. J Am Chem Soc. 2011;133:12624–12631
Wagner M, Wagner S, Schnorr J, et al. Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging. 2011;34:816–823
Rui Y, Liang B, Hu F, et al. Ultra-large-scale production of ultrasmall superparamagnetic iron oxide nanoparticles for T1-weighted MRI. RSC Adv. 2016;6:22575–22585
Vangijzegem T, Stanicki D, Boutry S, et al. VSION as high field MRI T1 contrast agent: evidence of their potential as positive contrast agent for magnetic resonance angiography. Nanotechnology. 2018;29:1–14
Pham HN, Pham THG, Nguyen DT, et al. Magnetic inductive heating of organs of mouse models treated by copolymer coated Fe3O4 nanoparticles. Adv Nat Sci Nanosci Nanotechnol. 2017;8:1–10
Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995–4021
Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8:147–166
Karageorgis A, Dufort S, Sancey L, et al. An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors. Sci Rep. 2016;6:1–10
Nichols JW, Bae YH. EPR: evidence and fallacy. J Control Release. 2014;190:451–464
Ulbrich K, Holá K, Subr V, et al. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116:5338–5431
Bietenbeck M, Florian A, Faber C, et al. Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now? Int J Nanomed. 2016;11:3191–3203
Kumar JP, Prasad GK, Ramacharyulu PVRK, et al. Synthesis, characterization, and studies on decontamination of sulfur mustard. J Alloys Compd. 2017;692:833–840
Sheng-Nan S, Chao W, Zan-Zan Z, et al. Magnetic iron oxide nanoparticles: synthesis and surface coating techniques for biomedical applications. Chin Phys B. 2014;23:1–19
Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008;108:2064–2110
Hola K, Markova Z, Zoppellaro G, et al. Tailored functionalization of iron oxide nanoparticles for MRI, drug delivery, magnetic separation and immobilization of biosubstances. Biotechnol Adv. 2015;33:1162–1176
Kumar CSSR, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug-delivery. Adv Drug Deliv Rev. 2011;63:789–808
Teja AS, Koh P. Synthesis, properties, and applications of magnetic iron oxide nanoparticles. Prog Cryst Growth Charact Mater. 2009;55:22–45
Fu C, Ravindra NM. Magnetic iron oxide nanoparticles: synthesis and applications. Bioinspir Biomim Nan. 2012;1:229–244
Qiao R, Yang C, Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J Mat Chem. 2009;19:6274–6293
Pereira C, Pereira AM, Fernandes C, et al. Superparamagnetic MFe2O4 (M = Fe, Co, Mn) nanoparticles: tuning the particle size and magnetic properties through a novel one-step coprecipitation route. Chem Mater. 2012;24:1496–1504
Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn. 1981;17:1247–1248
Belaïd S, Laurent S, Vermeersch M, et al. A new approach to follow the formation of iron oxide nanoparticles synthesized by thermal decomposition. Nanotechnology. 2013;24:1–9
Belaïd S, Stanicki D, Vander Elst L, et al. Influence of experimental parameters on iron oxide nanoparticles properties synthesized by thermal decomposition: size and nuclear magnetic resonance studies. Nanotechnology. 2018;29:1–12
Stanicki D, Boutry S, Laurent S, et al. Carboxy-silane coated iron oxide nanoparticles: a convenient platform for cellular and small animal imaging. J Mat Chem B. 2014;2:387–397
Laurent S, Saei AA, Behzadi S, et al. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin Drug Deliv. 2014;11:1449–1470
Mallakpour S, Madani M. A review of current coupling agents for modification of metal oxide nanoparticles. Prog Org Coat. 2015;86:194–207
Mahmoudi M, Sant S, Wang B, et al. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev. 2011;63:24–46
Gupta AK, Naregalkar RR, Vaidya VD, et al. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine. 2007;2:23–39
N.T.K.Thanh. Clinical applications of magnetic nanoparticles. Boca Raton: CRC Press; 2018
Ling D, Lee N, Hyeon T. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Acc Chem Res. 2015;48:1276–1285
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30
Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79
Estanqueiro M, Amaral MH, Conceição J, et al. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces. 2015;126:631–648
Cole AJ, Yang VC, David AE. Cancer theranostics: the rise of targeted nanoparticles. Trends Biotechnol. 2011;29:323–332
Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440–446
Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:1–11
Kampan N, Madondo M, McNally O, et al. Paclitaxel and its evolving role in the management of ovarian cancer. BioMed Res Int. 2015;2015:1–21
Konstat-Korzenny E, Ascencio-Aragón J, Niezen-Lugo S, et al. Artemisinin and its synthetic derivatives as a possible therapy for cancer. Med Sci. 2018;6:1–10
Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012;2012:1–18
Cavalcante LS, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8–16
Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239–253
Kane RC, Bross PF, Farrell AT, et al. Velcade®:U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508–513
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2015;5:364–378
Herbst RS, Khuri FR. Mode of action of docetaxel–a basis for combination with novel anticancer agents. Cancer Treat Rev. 2003;29:407–415
Xie J, Chen K, Huang J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010;31:3016–3022
Quan Q, Xie J, Gao H, et al. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol Pharm. 2011;8:1669–1676
Xie J, Wang J, Niu G. Human serum albumin coated iron oxide nanoparticles for efficient cell labelling. Chem Comm. 2010;46:433–435
Barenholz Y. Doxil®- The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134
Huang Y, Mao K, Zhang B, et al. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics. Mat Sci Eng C. 2017;70:763–771
Yang Y, Guo Q, Peng J, et al. Doxorubicin-conjugated heparin-coated superparamagnetic iron oxide nanoparticles for combined anticancer drug delivery and magnetic resonance imaging. J Biomed Nanotech. 2016;12:1963–1974
Estelrich J, Escribano E, Queralt J, et al. Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery. Int J Mol Sci. 2015;16:8070–8101
Issa B, Obaidat IM, Albiss BA, et al. Magnetic nanoparticles: surface effects and properties related to biomedicine applications. Int J Mol Sci. 2013;14:21266–21305
Wagstaff AJ, Brown SD, Holden MR, et al. Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorg Chim Acta. 2012;393:328–333
Lyon JL, Fleming DA, Stone MB, et al. Synthesis of Fe oxide core/Au shell nanoparticles by iterative hydroxylamine seeding. Nano Lett. 2004;4:719–723
Brown SD, Nativo P, Smith J, et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010;132:4678–4684
Craig GE, Brown SD, Lamprou DA, et al. Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval? Inorg Chem. 2012;51:3490–3497
Unterweger H, Tietze R, Janko C, et al. Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery. Int J Nanomedicine. 2014;9:3659–3676
Mattheolabakis G, Milane L, Singh A, et al. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23:605–618
Jeong Y, Kim S, Jin S, et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. Pharm Nanotechnol. 2008;97:1268–1276
Sugahara KN, Hirata T, Hayasaka H, et al. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861–5868
Nadeem M, Ahmad M, Akhtar MS, et al. Magnetic properties of polyvinyl alcohol and doxorubicine loaded iron oxide nanoparticles for anticancer drug delivery applications. PLoS ONE. 2016;11:1–12
Zaloga J, Janko C, Nowak J. Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility. Int J Nanomed. 2014;9:4847–4866
Zaloga J, Pöttler M, Leitinger G, et al. Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting. Eur J Pharm Biopharm. 2016;101:152–162
Natesan S, Ponnusamy C, Sugumaran A, et al. Artemisinin loaded chitosan magnetic nanoparticles for the efficient targeting to the breast cancer. Int J Biol Macromol. 2017;104:1853–1859
Rodrigues S, Dionísio M, López CR, et al. Biocompatibility of chitosan carriers with application in drug delivery. J Funct Biomater. 2012;3:615–641
Thapa D, Palkar VR, Kurup MB, et al. Properties of magnetite nanoparticles synthesized through a novel chemical route. Matt Lett. 2004;58:2692–2694
Calvo P, Remuñán-López C, Vila-Jato JL, et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63:125–132
Jeon H, Kim J, Lee YM, et al. Poly-paclitaxel/cyclodextrin-SPION nano-assembly for magnetically guided drug delivery system. J Control Release. 2016;231:68–76
Du X, Khan AR, Fu M, et al. Current development in the formulations of non-injection administration of paclitaxel. Int J Pharm. 2018;542:242–252
Veiseh O, Gunn JW, Zhang M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev. 2010;62:284–304
Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7:2078–2089
Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997;75:388–395
Mu Q, Kievit FM, Kant RJ, et al. Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. Nanoscale. 2015;7:18010–18014
Ahmed MSU, Salam AB, Yates C, et al. Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer. Int J Nanomed. 2017;12:6973–6984
Nagesh PKB, Johnson NR, Boya VKN, et al. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B. 2016;144:8–20
Leach JC, Wang A, Ye K, et al. A RNA-DNA hybrid aptamer for nanoparticle-based prostate tumor targeted drug delivery. Int J Mol Sci. 2016;17:1–11
Aires A, Ocampo SM, Simões BM. Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology. 2016;27:1–10
Latorre A, Couleaud P, Aires A, et al. Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach. Eur J Med Chem. 2014;82:355–362
Trabulo S, Aires A, Aicher A, et al. Multifunctionalized iron oxide nanoparticle for selective targeting of pancreatic cancer cells. Biochim Biophys Acta. 2017;1861:1597–1605
Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12:991–1003
Karimi M, Eslami M, Sahandi-Zangabad P. pH-sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. WIREs Nanomed Nanobiotechnol. 2016;8:696–716
Kievit FM, Wang FY, Fang C, et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release. 2011;152:76–83
Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–234
Fang C, Bhattarai N, Sun C, et al. Functionalized nanoparticles with long-term stability in biological media. Small. 2009;5:1637–1641
Gautier J, Munnier E, Paillard A, et al. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting. Int J Pharm. 2012;423:16–25
Hervé K, Douziech-Eyrolles L, Munnier E, et al. The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications. Nanotechnology. 2008;19:1–7
Munnier E, Cohen-Jonathan S, Linassier C, et al. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting. Pharm Nanotechnol. 2008;363:170–176
Wimardhani YS, Suniarti DF, Freisleben HJ, et al. Chitosan exerts anticancer activity through induction of apoptosis and cell cycle arrest in oral cancer cells. J Oral Sci. 2014;56:119–126
Dash M, Chiellini F, Ottenbrite RM, et al. Chitosan–A versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci. 2011;36:981–1014
Unsoy G, Yalcin S, Khodadust R, et al. Chitosan magnetic nanoparticles for pH responsive bortezomib release in cancer therapy. Biomed Pharmacother. 2014;68:641–648
Unsoy G, Yalcin S, Khodadust R, et al. Synthesis optimization and characterization of chitosan-coated iron oxide nanoparticles produced for biomedical applications. J Nanopart Res. 2012;14:1–13
Unsoy G, Khodadust R, Yalcin S, et al. Synthesis of doxorubicin loaded magnetic chitosan nanoparticles for pH responsive targeted drug delivery. Eur J Pharm Sci. 2014;62:243–250
Adimoolam MG, Amreddy N, Nalam MR, et al. A simple approach to design chitosan functionalized Fe3O4 nanoparticles for pH responsive delivery of doxorubicin for cancer therapy. J Magn Magn Mater. 2018;448:199–207
Zou Y, Liu P, Liu C, et al. Doxorubicin-loaded mesoporous magnetic nanoparticles to induce apoptosis in breast cancer cells. Biomed Pharmacother. 2015;69:355–360
Quinto CA, Mohindra P, Tong S, et al. Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment. Nanoscale. 2015;7:12728–12736
Nguyen VH, Lee B. Protein corona: a new approach for nanomedicine design. Int J Nanomed. 2017;12:3137–3151
Pederzoli F, Tosi G, Vandelli MA, et al. Protein corona and nanoparticles: how can we investigate on? WIREs Nanomed Nanobiotechnol. 2017;9:1–23
